Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 entities : Evelo biosciences, inc. save search
Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
Published: 2023-10-17 (Crawled : 11:00) - globenewswire.com
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: -62.87%
H: 55.26%
C: 5.26%
edp2939 psoriasis results study phase 2
Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial
Published: 2023-02-27 (Crawled : 14:00) - biospace.com/
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: 5.0%
H: 1.2%
C: -6.57%
edp2939 trial psoriasis phase 2
Evelo Biosciences Presents Late-Breaking Oral Abstract on Data from Phase 2 Trial of EDP1815 in Psoriasis at 2022 American Academy of Dermatology Annual Meeting
Published: 2022-03-26 (Crawled : 16:20) - globenewswire.com
EVLO | $0.3165 -87.39% 710K
|
Health Technology
| Email alert
Add to watchlist
edp1815 trial psoriasis phase 2
Durable and Deepening Clinical Responses Observed in Post-Treatment Period of Evelo Bioscience’s Phase 2 Clinical Trial of Oral EDP1815 in Psoriasis
Published: 2022-02-28 (Crawled : 12:00) - biospace.com/
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: 0.0%
H: 2.64%
C: -8.36%
edp1815 treatment phase 2 trial response psoriasis pons bioscience
Evelo Biosciences Announces Dosing of First Patient in Phase 2 Trial of EDP1815 in Atopic Dermatitis
Published: 2022-02-17 (Crawled : 13:30) - biospace.com/
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: 1.25%
H: 0.0%
C: -10.37%
edp1815 phase 2 atopic dermatitis dermatitis derm trial bioscience
Evelo Biosciences Announces Highly Significant Reductions in Clinically Validated Inflammatory Cytokines in EDP1815 Phase 2 Psoriasis Trial
Published: 2022-02-07 (Crawled : 13:30) - biospace.com/
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: 5.75%
H: 0.0%
C: -4.35%
edp1815 phase 2 trial psoriasis bioscience
Evelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis; Confirms Ability to Harness the Small Intestinal Axis, SINTAX™, to Treat Systemic Inflammatory Disease
Published: 2021-09-27 (Crawled : 08:00) - biospace.com/
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: -17.39%
H: 28.38%
C: 21.04%
disease phase 2 test positive psoriasis
Evelo Biosciences Announces New Clinical Candidate in Oncology and Presents Additional Interim Data from Phase 1/2 Clinical Trial of EDP1503 in Patients with Triple-Negative Breast Cancer
Published: 2020-12-09 (Crawled : 14:04) - globenewswire.com
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: 7.06%
H: 35.6%
C: 14.26%
breast cancer cancer trial phase 3 phase 1 phase 2
Evelo Biosciences Completes Enrollment to Interim Target in Phase 2 Trial Evaluating EDP1815 for the Treatment of Psoriasis
Published: 2020-12-03 (Crawled : 12:01) - globenewswire.com
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: -0.6%
H: 4.0%
C: 0.4%
trial treatment phase 2 psoriasis enroll
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.